Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tarun Dalia

Advanced Heart Failure and Transplant Cardiology Kansas City, KS Medical Doctor

NPI 1700235678 CMS profile 2351901

4000 Cambridge St Ste G600, Kansas City, KS 66160

Open in the dashboard

General payments

$15,734

247 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$677 paid to institutions, not to them · program year 2025

Through program year 2025, Tarun Dalia of Kansas City, KS is reported in the CMS Open Payments database as having received $15,734 across 247 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $677 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 63rd percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,302 77
2024 General $3,652 68
2023 General $3,532 43
2022 General $3,419 34
2021 General $757 9
2020 General $499 8
2019 General $572 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tarun Dalia
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Tarun Dalia were reported at $3,302. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Tarun Dalia Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $572 $863 $224–$4,562 $163
2020 $499 $452 $122–$3,992 $114
2021 $757 $550 $159–$3,571 $132
2022 $3,419 $729 $221–$4,357 $149
2023 $3,532 $1,002 $309–$5,827 $160
2024 $3,652 $931 $273–$5,204 $164
2025 $3,302 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $8,884 100 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,247 25 payments
  3. AstraZeneca Pharmaceuticals LP $732 17 payments
  4. Abiomed $708 6 payments
  5. Impulse Dynamics (USA) Inc. $474 10 payments
  6. Medtronic, Inc. $466 6 payments
  7. Boston Scientific Corporation $442 4 payments
  8. Alnylam Pharmaceuticals Inc. $433 5 payments
  9. Endotronix, Inc. $327 3 payments
  10. Merck Sharp & Dohme Corporation $317 18 payments
  11. Other $1,702 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,983 221 payments
  2. Travel and Lodging $4,221 21 payments
  3. Education $529 5 payments
Products named General payments · program years 2019–2025
  1. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Heart failure $3,564 37 payments
  2. CARDIOMEMS Heart failure $2,402 20 payments
  3. CARDIOMEMS Structural Heart $1,303 22 payments
  4. LifeVest $1,247 25 payments
  5. Impella $691 5 payments
  6. OPTIMIZER Cardiovascular Device $474 10 payments
  7. OPTIMIZER Cardiovascular Device $474 10 payments
  8. VERQUVO $455 26 payments
  9. AMVUTTRA $409 4 payments
  10. THORATEC HEARTMATE 3 LVAS IMPLANT KIT Structural Heart $371 7 payments
  11. Other $4,274 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

3,376

Median for Cardiology: 2,533

Drug cost

$1,051,516

Median for Cardiology: $485,213

Branded share of claims

30.3%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 308 $322,098
Entresto Sacubitril/Valsartan Brand 244 $306,468
Farxiga Dapagliflozin Propanediol Brand 140 $135,267
Eliquis Apixaban Brand 135 $125,589
Ozempic Semaglutide Brand 59 $64,596
Xarelto Rivaroxaban Brand 16 $21,394
Repatha Sureclick Evolocumab Brand 21 $16,055
Trulicity Dulaglutide Brand 15 $13,854
Bumetanide Generic 136 $6,674
Tacrolimus Generic 29 $4,185

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$82,695

Medicare's payments for the services billed

Medicare patients

387

Average age 72

Services billed

1,343

147 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Chronic kidney disease 60%
Atrial fibrillation 59%
Arthritis 52%
Diabetes 51%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAINUA
  • AstraZeneca Pharmaceuticals LP $283
$283 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $138
$138 — —
VYNDAQEL
  • PFIZER INC. $101
$101 — —
BRILINTA
  • AstraZeneca Pharmaceuticals LP $96
$96 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $52
$52 140 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record